Letter | Published:

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

Nature Medicine volume 17, pages 14981503 (2011) | Download Citation


Intra-abdominal tumors, such as ovarian cancer1,2, have a clear predilection for metastasis to the omentum, an organ primarily composed of adipocytes. Currently, it is unclear why tumor cells preferentially home to and proliferate in the omentum, yet omental metastases typically represent the largest tumor in the abdominal cavities of women with ovarian cancer. We show here that primary human omental adipocytes promote homing, migration and invasion of ovarian cancer cells, and that adipokines including interleukin-8 (IL-8) mediate these activities. Adipocyte–ovarian cancer cell coculture led to the direct transfer of lipids from adipocytes to ovarian cancer cells and promoted in vitro and in vivo tumor growth. Furthermore, coculture induced lipolysis in adipocytes and β-oxidation in cancer cells, suggesting adipocytes act as an energy source for the cancer cells. A protein array identified upregulation of fatty acid–binding protein 4 (FABP4, also known as aP2) in omental metastases as compared to primary ovarian tumors, and FABP4 expression was detected in ovarian cancer cells at the adipocyte-tumor cell interface. FABP4 deficiency substantially impaired metastatic tumor growth in mice, indicating that FABP4 has a key role in ovarian cancer metastasis. These data indicate adipocytes provide fatty acids for rapid tumor growth, identifying lipid metabolism and transport as new targets for the treatment of cancers where adipocytes are a major component of the microenvironment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , & Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26, 995–1005 (2008).

  2. 2.

    & Ovarian cancer. Annu. Rev. Pathol. 4, 287–313 (2009).

  3. 3.

    , , & Precursor to pelvic serous carcinoma and their clinical implications. Gynecol. Oncol. 113, 391–396 (2009).

  4. 4.

    Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053–1064 (2010).

  5. 5.

    Metabolism of isolated fat cells. J. Biol. Chem. 239, 375–380 (1964).

  6. 6.

    et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100, 359–372 (2008).

  7. 7.

    , & Interleukin-6 secreted by human ovarian carcinoma cells is a potent proangiogenic cytokine. Cancer Res. 65, 10794–10800 (2005).

  8. 8.

    , , & Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J. Pathol. 201, 221–228 (2003).

  9. 9.

    et al. Prostate cancer cell growth is modulated by adipocyte–cancer cell interaction. BJU Int. 91, 716–720 (2003).

  10. 10.

    et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455–2465 (2011).

  11. 11.

    et al. β3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am. J. Pathol. 175, 2184–2196 (2009).

  12. 12.

    , , & Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: Effect of estrogen and progesterone. Int. J. Cancer 51, 416–424 (1992).

  13. 13.

    & Fatty acid metabolism: target for metabolic syndrome. J. Lipid Res. 50, S138–S143 (2009).

  14. 14.

    & Signalling mechanisms regulating lipolysis. Cell. Signal. 18, 401–408 (2006).

  15. 15.

    et al. Involvement of a cGMP pathway in the natriuretic peptide–mediated hormone sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem. 278, 48617–48626 (2003).

  16. 16.

    , , , & Perilipin A and the control of triacylglycerol metabolism. Mol. Cell. Biochem. 326, 15–21 (2009).

  17. 17.

    et al. Thyroid-stimulating hormose stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo. Metabolism 59, 547–553 (2010).

  18. 18.

    & AMP-activated protein kinase and cancer. Acta Physiol. (Oxf.) 196, 55–63 (2009).

  19. 19.

    , , & Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331–338 (1988).

  20. 20.

    et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-β pathway signaling indicates response to primary chemotherapy. Clin. Cancer Res. 16, 2852–2860 (2010).

  21. 21.

    et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274, 1377–1379 (1996).

  22. 22.

    & Fatty acid binding proteins: Role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7, 489–503 (2008).

  23. 23.

    et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2−/− mice. Diabetes 48, 1987–1994 (1999).

  24. 24.

    et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447, 959–965 (2007).

  25. 25.

    et al. Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J. Med. Chem. 52, 6024–6031 (2009).

  26. 26.

    , , , & Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141, 3388–3396 (2000).

  27. 27.

    et al. The autophagic tumor stroma model of cancer or “battery-operated tumor growth” a simple solution to the autophagy paradox. Cell Cycle 9, 4297–4306 (2010).

  28. 28.

    et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984–4001 (2009).

  29. 29.

    & The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340–1344 (2010).

  30. 30.

    , , & The biology of cancer: Metabolic programming fuels cell growth and proliferation. Cell Metab. 7, 11–20 (2008).

  31. 31.

    Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9, 230–234 (2006).

  32. 32.

    et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041–1051 (2011).

  33. 33.

    , , , & Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726–734 (2011).

  34. 34.

    et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer 123, 476–483 (2008).

  35. 35.

    & Complementation analysis of fatty acid oxidation disorders. J. Clin. Invest. 79, 59–64 (1987).

  36. 36.

    et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteomics 6, 129–151 (2010).

Download references


We thank A.F. Haney (University of Chicago) for collecting omental biopsies and D. Bernlohr (University of Minnesota) for helpful discussions and kindly providing the FABP4 inhibitor. We thank S. Dogan for her contribution to the initiation of this project, G. Isenberg (University of Chicago) for editing the manuscript and A. Mitra (University of Chicago) for helpful discussions regarding the in vitro homing assay. We also thank K. Roby (University of Kansas Medical Center), N. Auersperg (University of British Columbia) and C. Clevenger (Northwestern University) for providing the ID8, IOSE and T47D cell lines, respectively. Finally, we thank all the patients, resident physicians and attending physicians in the Department of Obstetrics and Gynecology at the University of Chicago; without their commitment to tissue donation, this project would not have been possible. E.L. holds a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund. He is also supported by grants from the Ovarian Cancer Research Fund (Liz Tilberis Scholars Program), the US National Cancer Institute (R01 CA111882) and Bears Care, the charitable beneficiary of the Chicago Bears Football Club. K.M.N. is funded by a Cancer Biology Training Grant from the Committee on Cancer Biology at the University of Chicago and the National Cancer Institute (T32 CA959421). H.A.K. is supported by an award from the National Cancer Institute K99 CA134750). G.S.H. is supported by a grant from the US National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK064360).

Author information


  1. Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, Center for Integrative Science.

    • Kristin M Nieman
    • , Hilary A Kenny
    • , Carla V Penicka
    • , Andras Ladanyi
    • , Marion R Zillhardt
    • , Iris L Romero
    • , S Diane Yamada
    •  & Ernst Lengyel
  2. Department of Pathology, University of Chicago, Chicago, Illinois, USA.

    • Rebecca Buell-Gutbrod
    •  & Katja Gwin
  3. Department of Systems Biology, MD Anderson Cancer Center, Houston, Texas, USA.

    • Mark S Carey
    •  & Gordon B Mills
  4. Department of Genetics and Complex Diseases and the Broad Institute of Harvard University and Massachusetts Institute of Technology, Harvard School of Public Health, Boston, Massachusetts, USA.

    • Gökhan S Hotamisligil
  5. Feinberg School of Medicine, Division of Hematology and Oncology, Northwestern University, Chicago, Illinois, USA.

    • Marcus E Peter


  1. Search for Kristin M Nieman in:

  2. Search for Hilary A Kenny in:

  3. Search for Carla V Penicka in:

  4. Search for Andras Ladanyi in:

  5. Search for Rebecca Buell-Gutbrod in:

  6. Search for Marion R Zillhardt in:

  7. Search for Iris L Romero in:

  8. Search for Mark S Carey in:

  9. Search for Gordon B Mills in:

  10. Search for Gökhan S Hotamisligil in:

  11. Search for S Diane Yamada in:

  12. Search for Marcus E Peter in:

  13. Search for Katja Gwin in:

  14. Search for Ernst Lengyel in:


K.M.N. and H.A.K. performed most of the experiments. C.V.P. performed the western blots. M.R.Z., I.L.R. and C.V.P. assisted with some of the animal experiments. A.L., M.S.C. and G.B.M. performed and interpreted the protein array experiments. R.B.-G. and K.G. contributed to the immunohistochemistry for the human and mouse experiments. S.D.Y. and E.L. collected ovarian cancer tissues and clinicopathologic patient information. G.S.H. provided the Fabp4−/− mice and edited the manuscript. M.E.P. performed the bioinformatics analysis and edited the manuscript. K.M.N., H.A.K. and E.L. designed the experiments. K.M.N. and E.L. wrote the manuscript. E.L. directed the study.

Competing interests

The University of Chicago has filed for a patent application directed at the subject matter of this manuscript. G.S.H. has intellectual property related to blocking aP2 (FABP4) function for the treatment of metabolic diseases.

Corresponding author

Correspondence to Ernst Lengyel.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9 and Supplementary Methods

About this article

Publication history






Further reading